Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • ID: 3957568
  • Report
  • Region: Global
  • 70 Pages
  • GBI Research
1 of 4
Ophthalmology’s Diverse Pipeline Could Rejuvenate Previously Stagnant Therapy Area
Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and the visual system. The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse number of indications ranging from relatively mild conditions such as allergic conjunctivitis, which is characterized by inflammation of the eye as a result of an allergy, to vision-threatening conditions such as macular degeneration.

The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse range of indications affecting this system, which range from relatively mild conditions such as allergic conjunctivitis, which is characterized by inflammation of the eye as a result of an allergy, to more vision-threatening conditions such as macular degeneration or glaucoma.

Scientific advancements in recent decades have revealed a broad range of novel potential molecular targets, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 pipeline products currently in the ophthalmology therapy area pipeline.

The ophthalmology pipeline has a highly active deals landscape. There were 332 licensing deals and 194 co-development deals completed between 2006 and 2016 across the therapy area, of which 114 licensing deals and 40 co-development deals had a disclosed value. The aggregate disclosed value for these licensing deals was $20.9 billion, and for co-development deals this figure was $12.9 billion. This indicates a high level of deal-making activity and a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations in order to mitigate some of the risks associated with drug development.

According to Dominic Trewartha, “The ophthalmology pipeline contains a diverse range of molecular targets and no single target dominates by any clear margin. However, products acting on components of the immune system - largely cytokine and cytokine receptors - and its regulatory signaling pathways make up the largest segment, followed by angiogenesis inhibitors”.

The report “Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way” provides the analysis of innovation in the ophthalmology markets in the context of the overall pipeline and current market landscape.

In particular, this report provides the following analysis:
  • Provides a brief introduction to ophthalmology, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Helps to identify and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Market Landscape Poised for Entry of Novel Products
2.2 Moderately-Sized but Strong First-in-Class Pipeline
2.3 Strong Uptake of First-in-Class Products in Strategic Consolidations

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.1.1 Glaucoma
4.1.2 Age-related Macular Degeneration
4.1.3 Diabetic Macular Edema
4.1.4 Diabetic Retinopathy
4.1.5 Dry Eye Syndrome
4.2 Disease Symptoms
4.3 Epidemiology and Etiology
4.3.1 Glaucoma
4.3.2 Age-related Macular Degeneration
4.3.3 Diabetic Retinopathy and Diabetic Macular Edema
4.3.4 Dry Eye Syndrome
4.4 Diagnosis
4.5 Pathophysiology
4.5.1 Healthy Eye Physiology
4.5.2 Glaucoma
4.5.3 Age-related Macular Edema
4.5.4 Diabetic Macular Edema and Diabetic Retinopathy
4.6 Treatment Options
4.7 Prognosis
4.7.1 Glaucoma
4.7.2 Age-Related Macular Degeneration
4.7.3 Diabetic Retinopathy and Diabetic Macular Edema
4.7.4 Dry Eye Syndrome
4.8 Overview of Marketed Products in Ophthalmology
4.8.1 Molecule Type and Target Analysis

5 Assessment of Pipeline Product Innovation
5.1 Ophthalmology Pipeline by Molecular Target
5.2 Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Ophthalmology
6.2 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting RPE65 and RBP4
7.2 Pipeline Programs Targeting Eotaxin-1 and CCR3
7.3 Pipeline Programs Targeting LRP6
7.4 Pipeline Programs Targeting TGF-Beta 2
7.5 Pipeline Programs Targeting NGF, and LNGFR and TrkA Nerve Growth Factor Receptors
7.6 Pipeline Programs Targeting Serine Protease HtrA1
7.7 Conclusion

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.2.1 Licensing Deals by Molecule Type
8.2.2 Licensing Deals by Molecular Target
8.2.3 Licensing Deals Valued Above $100m
8.3 Co-development Deals
8.3.1 Co-development Deals by Molecule Type
8.3.2 Co-development Deals by Molecular Target
8.3.3 Co-development Deals Valued Above $100m
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals

9 Appendix
9.1 Abbreviations
9.2 References
9.3 Research Methodology
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-development Deals
9.5 Contact Us
9.6 Disclaimer

1.1 List of Tables
Table 1: Ophthalmology Therapeutics Market, Main Symptoms of Glaucoma, AMD, DR and DES, 2016
Table 2: Ophthalmology Therapeutics Market, Prevalence of Major Ophthalmologic Disorders, 2016
Table 3: Ophthalmology Therapeutics Market, Treatment options available for glaucoma, 2016
Table 4: Ophthalmology Therapeutics Market, Data for RPE65 as a Molecular Target, 2016
Table 5: Ophthalmology Therapeutics Market, Data for RBP4 as a Molecular Target, 2016
Table 6: Ophthalmology Therapeutics Market, Data for CCR 3 as a Molecular Target, 2016
Table 7: Ophthalmology Therapeutics Market, Data for Eotaxin-1 as a Molecular Target, 2016
Table 8: Ophthalmology Therapeutics Market, Data for LRP6 as a Molecular Target, 2016
Table 9: Ophthalmology Therapeutics Market, Data for TGF- Beta 2 as a Molecular Target, 2016
Table 10: Ophthalmology Therapeutics Market, Data for LNGFR as a Molecular Target, 2016
Table 11: Ophthalmology Therapeutics Market, Data for TrkA as a Molecular Target, 2016
Table 12: Ophthalmology Therapeutics Market, Data for NGF as a Molecular Target, 2016
Table 13: Ophthalmology Therapeutics Market, Data for Serine Protease HTRA1 as a Molecular Target, 2016

1.2 List of Figures
Figure 1: Ophthalmology Therapeutics Market, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2012
Figure 2: Ophthalmology Therapeutics Market, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval ($m)
Figure 3: Ophthalmology Therapeutics Market, Overview of Marketed Products, 2016
Figure 4: Ophthalmology Therapeutics Market, Overview of Pipeline Products, 2016
Figure 5: Ophthalmology Therapeutics Market, Pipeline by Stage of Development and Molecule Type, 2016
Figure 6: Ophthalmology Therapeutics Market, Pipeline by Key Indications and Stage of Development, 2016
Figure 7: Ophthalmology Therapeutics Market, Pipeline by Key Indications and Molecular Type, 2016
Figure 8: Ophthalmology Therapeutics Market, Pipeline by Molecular Target, 2016
Figure 9: Ophthalmology Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2016
Figure 10: Ophthalmology Therapeutics Market, Pipeline by Key Indications and Molecular Target, 2016
Figure 11: Ophthalmology Therapeutics Market, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016
Figure 12: Ophthalmology Therapeutics Market, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016
Figure 13: Ophthalmology Therapeutics Market, Key Indications and Pipeline First-in-Class and Established Targets, 2016
Figure 14: Ophthalmology Therapeutics Market, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016
Figure 15: Ophthalmology Therapeutics Market, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016
Figure 16: Ophthalmology Therapeutics Market, First-in-Class Products in Pipeline (Part 1), 2016
Figure 17: Ophthalmology Therapeutics Market, First-in-Class Products in Pipeline (Part 2), 2016
Figure 18: Ophthalmology Therapeutics Market, First-in-Class Products in Pipeline (Part 3), 2016
Figure 19: Ophthalmology Therapeutics Market, Target Matrix Assessment (Part 1), 2016
Figure 20: Ophthalmology Therapeutics Market, Target Matrix Assessment (Part 2), 2016
Figure 21: Ophthalmology Therapeutics Market, Pipeline Programs Targeting RPE65, 2016
Figure 22: Ophthalmology Therapeutics Market, Pipeline Programs Targeting RBP4, 2016
Figure 23: Ophthalmology Therapeutics Market, Pipeline Programs Targeting CCR 3, 2016
Figure 24: Ophthalmology Therapeutics Market, Pipeline Programs Targeting Eotaxin-1, 2016
Figure 25: Ophthalmology Therapeutics Market, Pipeline Programs Targeting LRP 6, 2016
Figure 26: Ophthalmology Therapeutics Market, Pipeline Programs Targeting TGF-Beta 2, 2016
Figure 27: Ophthalmology Therapeutics Market, Pipeline Programs Targeting LNGFR, 2016
Figure 28: Ophthalmology Therapeutics Market, Pipeline Programs Targeting TrkA, 2016
Figure 29: Ophthalmology Therapeutics Market, Pipeline Programs Targeting NGF, 2016
Figure 30: Ophthalmology Therapeutics Market, Pipeline Programs Targeting Serine Protease HTRA1, 2016
Figure 31: Pharmaceutical Industry, Global, Deals by Stage of Development, 2006-2014
Figure 32: Pharmaceutical Industry, Global, Licensing Deal Values by Stage of Development ($m), 2006-2014
Figure 33: Ophthalmology Therapeutics Market, Licensing Deal Value, 2006-2016
Figure 34: Ophthalmology Therapeutics Market, Licensing Deals by Stage of Development, 2006-2016
Figure 35: Ophthalmology Therapeutics Market, Licensing Deals by Molecule Type, 2006-2016
Figure 36: Ophthalmology Therapeutics Market, Licensing Deals by Molecular Target, 2006-2016
Figure 37: Ophthalmology Therapeutics Market, Licensing Deals Valued Above $100m, 2006-2016
Figure 38: Ophthalmology Therapeutics Market, Co-Development Deal Value, 2006-2016
Figure 39: Ophthalmology Therapeutics Market, Co-Development Deals by Stage of Development, 2006-2016
Figure 40: Ophthalmology Therapeutics Market, Co-Development Deals by Molecule Type, 2006-2016
Figure 41: Ophthalmology Therapeutics Market, Co-Development Deals by Molecular Target, 2006-2016
Figure 42: Ophthalmology Therapeutics Market, Co-Development Deals Valued Above $100m, 2006-2016
Figure 43: Ophthalmology Therapeutics Market, First-in-Class Therapies Involved in Previous Deals, 2016
Figure 44: Ophthalmology Therapeutics Market, First-in-Class Therapies Not Involved in Previous Deals (Part 1), 2016
Figure 45: Ophthalmology Therapeutics Market, First-in-Class Therapies Not Involved in Previous Deals (Part 2), 2016

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll